FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894847654> ?p ?o ?g. }

• W2894847654 endingPage "39" @default.
• W2894847654 startingPage "33" @default.
• W2894847654 abstract "BackgroundThe HeartMate 3 left ventricular assist device (Abbott, Chicago, IL) is designed to provide circulatory support with enhanced hemocompatibility for patients with advanced heart failure. The purpose of this study was to compare the surgical outcomes between patients treated during the European Conformity Mark (CE Mark [CEM]) clinical trial and those treated in the postmarket era.MethodsThe prospective, observational, multinational ELEVATE (Evaluating the HeartMate 3 with Full MagLev Technology in a Post-Market Approval Setting) registry includes patients receiving the HeartMate 3 following CEM approval. Outcomes of patients in the ELEVATE registry are compared with patients in the CEM trial.ResultsCompared with the CEM trial (N = 50), the ELEVATE registry group (N = 463) was more severely ill, with more patients classified as INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profile 1 to 2 (32% versus 10%; p < 0.001). The CEM trial group was younger and underwent fewer concomitant valve procedures. After adjustment for differences in baseline characteristics, the 30-day survival was comparable between the ELEVATE registry and CEM trial groups (95% versus 98%; p = 0.46). Length of intensive care unit stay was similar between the ELEVATE registry (7 days) and CEM trial (6 days) groups. Most adverse event rates were comparable between the 2 groups. ELEVATE registry patients had a lower rate of cardiac arrhythmias (13% versus 28%; p = 0.009). With increasing experience, the implant technique has evolved to include more versatile approaches such as less invasive and off-pump implantation.ConclusionsThe 30-day outcomes for ELEVATE registry patients are comparable despite being sicker than CEM trial patients. Adverse event rates remain low, with no cases of pump thrombosis within the first 30 days. Implant techniques have evolved to include more versatile approaches. The HeartMate 3 left ventricular assist device (Abbott, Chicago, IL) is designed to provide circulatory support with enhanced hemocompatibility for patients with advanced heart failure. The purpose of this study was to compare the surgical outcomes between patients treated during the European Conformity Mark (CE Mark [CEM]) clinical trial and those treated in the postmarket era. The prospective, observational, multinational ELEVATE (Evaluating the HeartMate 3 with Full MagLev Technology in a Post-Market Approval Setting) registry includes patients receiving the HeartMate 3 following CEM approval. Outcomes of patients in the ELEVATE registry are compared with patients in the CEM trial. Compared with the CEM trial (N = 50), the ELEVATE registry group (N = 463) was more severely ill, with more patients classified as INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profile 1 to 2 (32% versus 10%; p < 0.001). The CEM trial group was younger and underwent fewer concomitant valve procedures. After adjustment for differences in baseline characteristics, the 30-day survival was comparable between the ELEVATE registry and CEM trial groups (95% versus 98%; p = 0.46). Length of intensive care unit stay was similar between the ELEVATE registry (7 days) and CEM trial (6 days) groups. Most adverse event rates were comparable between the 2 groups. ELEVATE registry patients had a lower rate of cardiac arrhythmias (13% versus 28%; p = 0.009). With increasing experience, the implant technique has evolved to include more versatile approaches such as less invasive and off-pump implantation. The 30-day outcomes for ELEVATE registry patients are comparable despite being sicker than CEM trial patients. Adverse event rates remain low, with no cases of pump thrombosis within the first 30 days. Implant techniques have evolved to include more versatile approaches." @default.
• W2894847654 created "2018-10-12" @default.
• W2894847654 creator A5009799168 @default.
• W2894847654 creator A5027485567 @default.
• W2894847654 creator A5028770050 @default.
• W2894847654 creator A5032814570 @default.
• W2894847654 creator A5037942613 @default.
• W2894847654 creator A5046346627 @default.
• W2894847654 creator A5046789711 @default.
• W2894847654 creator A5051809336 @default.
• W2894847654 creator A5058190750 @default.
• W2894847654 creator A5060099671 @default.
• W2894847654 creator A5083060460 @default.
• W2894847654 date "2019-01-01" @default.
• W2894847654 modified "2023-10-17" @default.
• W2894847654 title "Postmarket Experience With HeartMate 3 Left Ventricular Assist Device: 30-Day Outcomes From the ELEVATE Registry" @default.
• W2894847654 cites W155942078 @default.
• W2894847654 cites W1980668102 @default.
• W2894847654 cites W2059091774 @default.
• W2894847654 cites W2067943847 @default.
• W2894847654 cites W2075780056 @default.
• W2894847654 cites W2163772427 @default.
• W2894847654 cites W2187982610 @default.
• W2894847654 cites W2195045156 @default.
• W2894847654 cites W2281551311 @default.
• W2894847654 cites W2395468092 @default.
• W2894847654 cites W2485875098 @default.
• W2894847654 cites W2495267942 @default.
• W2894847654 cites W2522599581 @default.
• W2894847654 cites W2557028203 @default.
• W2894847654 cites W2563434462 @default.
• W2894847654 cites W2585810302 @default.
• W2894847654 cites W2587434344 @default.
• W2894847654 cites W2597245040 @default.
• W2894847654 cites W2604897515 @default.
• W2894847654 cites W2617669600 @default.
• W2894847654 cites W2625900314 @default.
• W2894847654 doi "https://doi.org/10.1016/j.athoracsur.2018.07.092" @default.
• W2894847654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30291831" @default.
• W2894847654 hasPublicationYear "2019" @default.
• W2894847654 type Work @default.
• W2894847654 sameAs 2894847654 @default.
• W2894847654 citedByCount "16" @default.
• W2894847654 countsByYear W28948476542019 @default.
• W2894847654 countsByYear W28948476542020 @default.
• W2894847654 countsByYear W28948476542021 @default.
• W2894847654 countsByYear W28948476542022 @default.
• W2894847654 crossrefType "journal-article" @default.
• W2894847654 hasAuthorship W2894847654A5009799168 @default.
• W2894847654 hasAuthorship W2894847654A5027485567 @default.
• W2894847654 hasAuthorship W2894847654A5028770050 @default.
• W2894847654 hasAuthorship W2894847654A5032814570 @default.
• W2894847654 hasAuthorship W2894847654A5037942613 @default.
• W2894847654 hasAuthorship W2894847654A5046346627 @default.
• W2894847654 hasAuthorship W2894847654A5046789711 @default.
• W2894847654 hasAuthorship W2894847654A5051809336 @default.
• W2894847654 hasAuthorship W2894847654A5058190750 @default.
• W2894847654 hasAuthorship W2894847654A5060099671 @default.
• W2894847654 hasAuthorship W2894847654A5083060460 @default.
• W2894847654 hasBestOaLocation W28948476541 @default.
• W2894847654 hasConcept C126322002 @default.
• W2894847654 hasConcept C141071460 @default.
• W2894847654 hasConcept C168563851 @default.
• W2894847654 hasConcept C194828623 @default.
• W2894847654 hasConcept C197934379 @default.
• W2894847654 hasConcept C23131810 @default.
• W2894847654 hasConcept C2776376669 @default.
• W2894847654 hasConcept C2778198053 @default.
• W2894847654 hasConcept C2778774980 @default.
• W2894847654 hasConcept C535046627 @default.
• W2894847654 hasConcept C71924100 @default.
• W2894847654 hasConceptScore W2894847654C126322002 @default.
• W2894847654 hasConceptScore W2894847654C141071460 @default.
• W2894847654 hasConceptScore W2894847654C168563851 @default.
• W2894847654 hasConceptScore W2894847654C194828623 @default.
• W2894847654 hasConceptScore W2894847654C197934379 @default.
• W2894847654 hasConceptScore W2894847654C23131810 @default.
• W2894847654 hasConceptScore W2894847654C2776376669 @default.
• W2894847654 hasConceptScore W2894847654C2778198053 @default.
• W2894847654 hasConceptScore W2894847654C2778774980 @default.
• W2894847654 hasConceptScore W2894847654C535046627 @default.
• W2894847654 hasConceptScore W2894847654C71924100 @default.
• W2894847654 hasIssue "1" @default.
• W2894847654 hasLocation W28948476541 @default.
• W2894847654 hasLocation W28948476542 @default.
• W2894847654 hasOpenAccess W2894847654 @default.
• W2894847654 hasPrimaryLocation W28948476541 @default.
• W2894847654 hasRelatedWork W1984720268 @default.
• W2894847654 hasRelatedWork W2030936866 @default.
• W2894847654 hasRelatedWork W2103779230 @default.
• W2894847654 hasRelatedWork W2109147503 @default.
• W2894847654 hasRelatedWork W2322581019 @default.
• W2894847654 hasRelatedWork W2383994333 @default.
• W2894847654 hasRelatedWork W3141050733 @default.
• W2894847654 hasRelatedWork W334096847 @default.
• W2894847654 hasRelatedWork W4381328000 @default.
• W2894847654 hasRelatedWork W588655279 @default.
• W2894847654 hasVolume "107" @default.

• next